Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bone: bone density screening leads to reduced fracture risk.

× No keyword cloud information.

7 in total

1. Screening for osteoporosis in postmenopausal women: recommendations and rationale.

Authors:
Journal: Ann Intern Med Date: 2002-09-17 Impact factor: 25.391

2. Osteoporosis disease management: the role of the orthopaedic surgeon.

Authors: Richard Dell; Denise Greene; Steven R Schelkun; Kathy Williams
Journal: J Bone Joint Surg Am Date: 2008-11 Impact factor: 5.284

3. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.

Authors: Nelson B Watts; E Michael Lewiecki; Paul D Miller; Sanford Baim
Journal: J Clin Densitom Date: 2008-06-18 Impact factor: 2.617

4. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk.

Authors: R J Barr; A Stewart; D J Torgerson; D M Reid
Journal: Osteoporos Int Date: 2009-06-30 Impact factor: 4.507

5. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years.

Authors: E D Newman; W T Ayoub; R H Starkey; J M Diehl; G C Wood
Journal: Osteoporos Int Date: 2003-02-18 Impact factor: 4.507

Review 6. Treatment of postmenopausal osteoporosis.

Authors: Pierre D Delmas
Journal: Lancet Date: 2002-06-08 Impact factor: 79.321

7. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors: D Marshall; O Johnell; H Wedel
Journal: BMJ Date: 1996-05-18

7 in total

2 in total

1. siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.

Authors: Yuwei Wang; David W Grainger
Journal: Pharm Res Date: 2010-03-24 Impact factor: 4.200

2. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors: Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal: Clin Genitourin Cancer Date: 2013-07-05 Impact factor: 2.872

2 in total